about
Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cellsUV-induced DNA incision and proliferating cell nuclear antigen recruitment to repair sites occur independently of p53-replication protein A interaction in p53 wild type and mutant ovarian carcinoma cellsSynergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivoApoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response.Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids.Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response.PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis.Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.Sensitization of tumor cells by targeting histone deacetylases.Targeting DNA topoisomerase I with non-camptothecin poisons.Namitecan: a hydrophilic camptothecin with a promising preclinical profile.Drug combinations with proteasome inhibitors in antitumor therapy.Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.New macrocyclic analogs of the natural histone deacetylase inhibitor FK228; design, synthesis and preliminary biological evaluation.miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis.[1,2]Oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors.Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma.3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity.Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors.Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.Quinazolinecarboline alkaloid evodiamine as scaffold for targeting topoisomerase I and sirtuins.Camptothecin-7-yl-methanthiole: semisynthesis and biological evaluation.Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors.Proteomic analysis of cellular response to novel proapoptotic agents related to atypical retinoids in human IGROV-1 ovarian carcinoma cells.Modulation of cell sensitivity to antitumor agents by targeting survival pathways.Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968.Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.Synthesis, modelling, and antimitotic properties of tricyclic systems characterised by a 2-(5-Phenyl-1H-pyrrol-3-yl)-1,3,4-oxadiazole moiety.Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity.Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response.
P50
Q28208972-923AE799-C8EB-4B90-89D7-7F9E4295AB7CQ28212579-F8390C11-B9A4-40FB-ACCE-2E190B1EF668Q28741274-F667D926-9CFE-46A1-8C6B-B24E984CD6EBQ30874066-FA762746-A0B6-423E-8890-60304C010832Q33285091-7DDC3ACE-52CE-4D92-B4EA-C61FCA51C5EEQ33493109-8E03BB07-82BB-4F3B-AA37-788523729A40Q35832219-3FF70665-5067-4774-9982-50D3DBA7E8CBQ36661719-78BDB584-2BA1-42CA-ACC7-7804827D105FQ37580294-EFB448E4-75F7-4C6E-A326-3C11D541C7CCQ37591581-06CB0482-A4DA-4D95-A67B-FADEF87AD532Q37961567-8E18353B-0E47-4020-83A1-B114E234F549Q37971946-02DF4897-B13B-4E98-892C-E4710208C0C7Q38017242-67D7F942-AFE0-4769-8F9A-B5C6230385FBQ38062570-7443D83A-3F44-43F2-A50E-3C96CCA0234EQ38081529-B499B5B6-B34A-4AA2-944E-962D4A74E5CDQ38611193-63A5509A-7044-4F51-A12B-66099B91C6A4Q38713064-E021B836-F86A-4958-B80B-4BAA146391DCQ38745258-C510A628-C691-4D34-B060-6BBDA1CC5CDAQ38757544-D6B179F8-6928-468F-B70D-6D6A49A80CD6Q38764064-CC714577-30E6-41D9-AC3F-9F66BF1FA5ACQ38834965-4FB85193-D0A4-4209-BA9F-1EB4ADBF125FQ38918627-C3B01F47-3141-486C-ACD4-202DE1AE5E20Q39003249-07A8AC85-B7AE-4571-8831-141BE55DE4DEQ39044610-D198DFC3-2E74-48B4-BB63-6DDE8BD36A76Q39084606-B5206D44-E922-44BE-8669-5D486733C2CCQ39255471-91B5BC1D-BD98-4CEC-BEF5-15CDB507279BQ39357944-D0BE2234-544D-4AFA-A3A9-31791E0BEC5DQ39591543-6B030C7E-4A86-4F74-81C6-8D23E42D2AB9Q39622482-2F297F71-576C-43A2-991F-7773636D7A14Q39670793-C57856BA-30D8-4AF6-B1D2-9DE004A814D1Q39676578-5574938D-1903-422A-AF38-15E3AB527C84Q39690839-800BFE67-2A17-4554-A722-E131F763FEC7Q39757247-095D3126-6264-4820-B1C8-9ADE3035980CQ39797728-8D8FF93E-9D49-4FE6-8967-D18AF6D1810AQ39871914-3CF07818-E081-45E9-A765-DE030894911BQ39904908-4B601984-626C-4318-A73D-11DC50517015Q39958607-2B1C2021-D68E-46BB-A4C5-9C83E29A68F8Q40296990-0449C652-DAC7-4EA7-9885-B36276C419D0Q40395490-AA5E2E82-C1FB-4753-82E6-8C9008EBEA96Q40396313-630F2BCD-68AD-47FB-B474-8BF17330CFD0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Valentina Zuco
@ast
Valentina Zuco
@en
Valentina Zuco
@es
Valentina Zuco
@nl
Valentina Zuco
@sl
type
label
Valentina Zuco
@ast
Valentina Zuco
@en
Valentina Zuco
@es
Valentina Zuco
@nl
Valentina Zuco
@sl
prefLabel
Valentina Zuco
@ast
Valentina Zuco
@en
Valentina Zuco
@es
Valentina Zuco
@nl
Valentina Zuco
@sl
P106
P21
P31
P496
0000-0001-7882-9095